Duality Biotherapeutics (DualityBio) has released its AGM circular, detailing several resolutions to be put to shareholders at the meeting on 26 Jun 2026 in Shanghai.

Key proposals 1. Share repurchase mandate: Directors are seeking authority to buy back up to 9,037,661 shares—equivalent to 10% of the current 90,376,614 issued shares (treasury shares excluded). The mandate would run until the next AGM, earlier revocation or expiry. 2. Issuance mandate: The Board also requests approval to allot, issue or transfer up to 18,075,322 additional shares, representing 20% of issued share capital, with an extension option equal to any shares repurchased under the buyback mandate. 3. Director re-elections: Executive Director Dr Hua Haiqing, Non-executive Director Mr Cai Zhiyang, and Independent Non-executive Directors Mr Xie Dong and Ms Chuai Shuyin are standing for re-election. 4. Auditor re-appointment: PricewaterhouseCoopers is nominated to continue as external auditor; total remuneration for interim review and FY 2026 audit is estimated at RMB 2.70 million.

Recent treasury-share activity Between 26 May and 4 Jun 2026 DualityBio repurchased 255,400 shares on the Hong Kong Stock Exchange for HK$ 53.31 million; these shares are being held in treasury.

Administrative details • Register closure: 23–26 Jun 2026 (both dates inclusive). Share transfers must be lodged by 16:30 on 22 Jun 2026. • Voting: All resolutions will be decided by poll; proxy forms must be submitted no later than 24 Jun 2026.

If approved, the mandates will provide the Board with additional flexibility for capital management and funding over the next year.